COVID-19 Evidence Accelerator: A parallel analysis to describe the use of Hydroxychloroquine with or without Azithromycin among hospitalized COVID-19 patients.

摘要: Background The COVID-19 pandemic remains a significant global threat. However, despite urgent need, there uncertainty surrounding best practices for pharmaceutical interventions to treat COVID-19. In particular, conflicting evidence has emerged the use of hydroxychloroquine and azithromycin, alone or in combination, Evidence Accelerator convened by Reagan-Udall Foundation FDA, collaboration with Friends Cancer Research, assembled experts from health systems research, regulatory science, data epidemiology participate large parallel analysis different sets further explore effectiveness these treatments. Methods Electronic record (EHR) claims were extracted seven separate databases. Parallel analyses undertaken on each source. Each examined time mortality hospitalized patients treated hydroxychloroquine, two combination as compared not either drug. Cox proportional hazards models used, propensity score methods adjust confounding. Frequencies adverse events treatment group also examined. Results Neither nor significantly associated among patients. No groups appeared have an elevated risk events. Conclusion Administration their no effect Continued research is needed clarify